Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2.

Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2.

Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.

Imazapic is a selective herbicide for both the preand post-emergent control of some annual and perennial grasses and some broadleaf weeds

Imazaquin is an imidazolinone herbicide that effectively controls a broad spectrum of weed species, by inhibiting acetohydroxy acid synthase (AHAS)..

IMB-301 (NSC 301209) is a small molecule inhibitor that target the binding interface of the HIV-1 Vif/hA3G complex, inhibits the replication of HIV-1 in H9 cells (IC50=8.63 uM).

iMDK is a small molecule inhibitor of the growth factor Midkine (MDK) that suppresses the endogenous expression of MDK but not other growth factors such as PTN or VEGF.

Imidazole is a heterocyclic aromatic organic compound. It can be incorporated into many important biological molecules and acts as a corrosion inhibitor for industrial applications.

Imidazole-4(5)-acetic Acid Hydrochloride is a competitive antagonist at GABAC receptors.

Imipenem (MK-0787) is a broad-spectrum, semi-synthetic beta-lactam carbapenem that has broad antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains..

Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.

IMM-01 is a small molecule agonist of mammalian Diaphanous (mDia)-related formins that disrupts diaphanous inhibitory domain (DID) and diaphanous autoregulatory domain (DAD) interaction with IC50 of 140 nM.

IMM-02 is a small molecule agonist of mammalian Diaphanous (mDia)-related formins that disrupts diaphanous inhibitory domain (DID) and diaphanous autoregulatory domain (DAD) interaction with IC50 of 99 nM.

IMP-1088 is a novel picomolar dual inhibitor of the human N-myristoyltransferases NMT1 and NMT2

IMTPPE (SID3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells.

In contrast to the estrogen receptor (ER) selectivity of (S)-equol , (R)-equol is a weaker ER agonist that binds to ERα and ERβ with Ki values of 27.4 and 15.4 nM, respectively.

INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively.

INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.

INCB057643 is a BET inhibitor that binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones.

INCB086550 is an orally available, small molecule inhibitor of PD-L1 with potential immune checkpoint inhibitory and antineoplastic activities. In vitro, INCB086550 selectively and potently blocked the PD-L1/PD-1 interaction, induced PD-L1 dimerization and internalization, and induced stimulation-dependent cytokine production in primary human immune cells. In vivo, INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade. Preliminary data from an ongoing phase I study confirmed PD-L1/PD-1 blockade in peripheral blood cells, with increased immune activation and tumor growth control.

INCB10820 (PF-4178903) is a potent, selective, orally bioavailable dual CCR2 and CCR5 antagonist with binding IC50 of 3.0 nM and 5.3 nM, respectively.

INCB3344 is a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor; inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC50 = 10 nM).